Study of Paclitaxel in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has
a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor
EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical®
does not contain Cremophor EL, hypersensitivity reactions can be expected to be less.
PURPOSE: To study the efficay and safety of two different formulations of paclitaxel,
Paclical® and Taxol®.